Core Viewpoint - The announcement reveals that the controlling shareholder and actual controller of Yiyigou, Li Yanfei, is transferring 5.23% of the company's total shares to board member Gan Meng at a price of 24 yuan per share, aiming to optimize the shareholder structure and enhance the company's competitive edge [1] Group 1 - The share transfer involves 5 million unrestricted circulating shares, representing 5.23% of the total share capital of Yiyigou [1] - The transfer price is set at 24 yuan per share, indicating a strategic move to bring in quality resources to support the company's development [1] - The transaction will not change the controlling shareholder or actual controller of the company, ensuring stability in governance [1] Group 2 - The company plans to collaborate with Gan Meng in areas such as industrial chain synergy, new business cultivation, and capital operations, aligning with its strategic layout [1] - The transfer is intended to introduce quality resources that will provide solid support for future business expansion and capital operations [1] - The announcement emphasizes the goal of enhancing the company's competitiveness and promoting sustainable development [1]

Core Viewpoint - The controlling shareholder and actual controller of Yiyigou, Ms. Li Yanfei, has signed a share transfer agreement to transfer 5 million unrestricted circulating shares, representing 5.23% of the company's total share capital, to Mr. Gan Meng at a price of 24.00 CNY per share, totaling 120 million CNY [1] Summary by Relevant Sections - **Share Transfer Details** - Ms. Li Yanfei will transfer 5 million shares, which is 5.23% of the total share capital of Yiyigou [1] - The transfer price is set at 24.00 CNY per share, leading to a total transaction value of 120 million CNY [1] - **Pricing Basis** - The share transfer price is based on the closing price of the shares in the secondary market on the trading day prior to the signing of the transfer agreement [1] - The pricing was mutually agreed upon by both parties and complies with relevant regulations [1]

Core Viewpoint - The share transfer agreement between Li Yanfei and Gan Meng signifies a strong commitment to the long-term development of Yao Yigou, with Gan Meng's 18-month lock-up period indicating confidence in the company's future value [1][2]. Group 1: Share Transfer Details - Li Yanfei is transferring 5 million unrestricted shares, representing 5.23% of the total share capital, for a total consideration of RMB 120 million [1]. - Gan Meng, a notable investor and newly appointed director of Yao Yigou, has committed to not reducing his stake for 18 months, which is significantly longer than typical market practices [1]. Group 2: Strategic Implications - The transaction is viewed as a positive signal, enhancing governance structure and decision-making capabilities, which may lead to improved risk management [1]. - Gan Meng's acquisition is based on his strong belief in the company's future prospects and investment value, indicating a shift from short-term financial investment to a long-term strategic partnership [1][2]. - The collaboration is expected to focus on industry chain synergy, new business development, and capital operations, aimed at boosting the company's competitive edge and sustainable growth [2].

Group 1 - The core point of the news is that the controlling shareholder of Yiyigou, Li Yanfei, has signed a share transfer agreement with Gan Meng, transferring 5.23% of the company's total shares for a total price of 120 million RMB, aimed at optimizing the shareholder structure and introducing quality resources for the company's development [1] - The share transfer is not intended to seek control of the company, but rather to enhance the company's competitiveness and support its sustainable development through collaboration in areas such as industrial chain synergy and new business cultivation [1] - Gan Meng, who is a board member of Sichuan Hezhong Yiyigou Pharmaceutical Co., Ltd., will participate in the company's long-term strategic planning and major investment decisions, bringing valuable experience to the company [1] Group 2 - Gan Meng emphasizes the need for medical innovation to focus on patient value, advocating for technology development that addresses clinical needs rather than merely pursuing commercialization [2] - He believes that the core competitiveness of digital healthcare lies in "data-driven precision diagnosis," which requires establishing industry standards through multi-center clinical research [2] - Gan Meng's involvement is expected to drive the company's transformation towards an "pharmaceutical + technology + health" ecosystem [2]

Core Viewpoint - The company announced a share transfer agreement where the controlling shareholder, Li Yanfei, will transfer 5 million unrestricted circulating shares, representing 5.23% of the total share capital, to Gan Meng [1] Group 1: Shareholder Changes - Following the share transfer, the combined shareholding of Li Yanfei and his concerted parties, including Zhou Yuebing, Li Jin, and Chengdu Heqi Investment Management Center (Limited Partnership), will decrease from 43.98% to 38.75% [1] - The share transfer will not result in a change of the company's controlling shareholder or actual controller [1] Group 2: Regulatory Compliance - The share transfer is subject to compliance confirmation by the Shenzhen Stock Exchange and the completion of share transfer registration procedures [1]

Core Viewpoint - The announcement reveals that the controlling shareholder and actual controller of the company, Li Yanfei, has signed a share transfer agreement with Gan Meng to transfer 5 million unrestricted circulating shares, representing 5.23% of the total share capital, at a price of 24 yuan per share, totaling 120 million yuan [1] Group 1 - The share transfer will reduce Li Yanfei and his concerted parties' shareholding from 43.98% to 38.75% [1] - Gan Meng will acquire a shareholding of 5.23% following the transfer [1] - The transaction does not trigger a mandatory tender offer, does not constitute a related party transaction, and will not result in a change of the company's controlling shareholder or actual controller [1]

上市公司名称：四川合纵药易购医药股份有限公司 股份变动性质：股份减少（协议转让） 签署日期：2025年11月10日 1 股票上市地点：深圳证券交易所 股票简称：药易购 股票代码：300937 信息披露义务人1：李燕飞 住所及通讯地址：四川省成都市 信息披露义务人2：周跃武 住所及通讯地址：四川省成都市 信息披露义务人3：李锦 住所及通讯地址：四川省成都市 信息披露义务人4：成都市合齐投资管理中心（有限合伙） 执行事务合伙人：李燕飞 住所及通讯地址：成都市金牛区沙湾东一路新2号明阳大厦1幢4层402 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司收购管理办法》《证券期货法律适用意见第19号——<上市 公司收购管理办法>第十三条、第十四条的适用意见》《公开发行证券的公司 信息披露内容与格式准则第15号——权益变动报告书》及其他相关法律、法规 和部门规章的有关规定编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《证券期 货法律适用意见第 ...

证券代码：300937 证券简称：药易购 公告编号：2025-048 四川合纵药易购医药股份有限公司 关于控股股东、实际控制人协议转让部分公司股份 暨权益变动的提示性公告 李燕飞女士与甘孟先生保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 近日，四川合纵药易购医药股份有限公司（以下简称"公司"）控股股东、 实际控制人李燕飞女士与境内自然人甘孟先生签署了《股份转让协议》（以下简 称"转让协议"），约定通过协议转让方式拟转让李燕飞女士持有的公司 500 万股无限售流通股股份（以下简称"标的股份"）给受让方，占公司总股本 5.23%。 本次股份转让价格为 24.00 元/股，交易总价为 12,000.00 万元。本次股份转 让价格系根据转让协议签署之日前一交易日转让股份二级市场收盘价为定价基 准，经双方协商一致确定，符合《上市公司收购管理办法》《深圳证券交易所上 市公司股份协议转让业务办理指引》等相关规定。 本次协议转让前，李燕飞女士及其一致行动人持有公司股份 42,071,000 股， 占公司总 ...

上市公司名称：四川合纵药易购医药股份有限公司 信息披露义务人：甘孟 住所及通讯地址：浙江省杭州市 股份变动性质：股份增加（协议转让） 签署日期：2025年11月10日 1 股票上市地点：深圳证券交易所 股票简称：药易购 股票代码：300937 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司收购管理办法》《证券期货法律适用意见第19号——<上市 公司收购管理办法>第十三条、第十四条的适用意见》《公开发行证券的公司 信息披露内容与格式准则第15号——权益变动报告书》及其他相关法律、法规 和部门规章的有关规定编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《证券期 货法律适用意见第19号——<上市公司收购管理办法>第十三条、第十四条的 适用意见》和《公开发行证券的公司信息披露内容与格式准则第15号——权益 变动报告书》的规定，本报告书已全面披露信息披露义务人在四川合纵药易购 医药股份有限公司中拥有权益的股份变动情况。截至本报告书签署日，除本报告 书披露的持股信息外，上述信息披露义务人没有通过任何其他方 ...

Shareholder Reduction Plans - Zhongjing Technology's shareholder Longi Green Energy plans to reduce holdings by no more than 3.8764 million shares [1] - Guobo Electronics' shareholder China Electronics Technology Group plans to reduce holdings by no more than 2.00% [1] - Hongbai New Materials' shareholder Xinyu Baolong plans to reduce holdings by no more than 19.5 million shares [1] - Founder Securities' shareholder China Cinda plans to reduce holdings by no more than 82.321 million shares [1] - Ningbo Zhongbai's shareholder Zhang Jiangbo plans to reduce holdings by no more than 1% [1] - Suli Co., Ltd.'s shareholder Gusheng Investment plans to reduce holdings by no more than 900,000 shares [1] - Ruihua Tai's shareholder Hangke New Century plans to reduce holdings by no more than 180,000 shares [1] - Shenkong's shareholder More Liangzhao plans to reduce holdings by no more than 2% [1] Other Notable Events - Yao Yigou received a tax matter notification [1] - ST Lingnan is being prosecuted for alleged collusion in bidding [1]